Study: Topical analgesics may be one answer to the opioid crisis
AUSTIN, Texas — Clarity Science, a division of Safe Harbor Compliance and Clinical Services, on Wednesday reported the results of the Institutional Review Board-approved Optimizing Patient Experience and Response to Topical Analgesics (OPERA) Study which evaluated patients with chronic pain who were treated with topical analgesics.
Overall results, published in the Journal of Pain Research, suggest that topical treatments may provide an effective and safer treatment alternative to opioids and prescription NSAIDs for the management of chronic pain.
"The results of this study show that topical analgesics were associated with reductions of up to 60% in the use of concurrent pain medications, including oral opioid analgesics," stated Jeffrey Gudin, lead investigator of the study and director Pain and Palliative Care at Englewood Hospital in New Jersey. "Topical agents have the potential to provide analgesic effects without the risk of abuse, misuse and addiction or systemic adverse events associated with oral analgesics. Also, they lower the risk of systemic AEs and drug-drug interactions, have limited systemic absorption, offer simple-dose determination, provide direct access to the target site and are easy for patients to apply."
Results of the study show that topical treatments are effective and safe for the relief of moderately severe chronic pain associated with arthritis, neuropathic conditions and musculoskeletal disorders while not carrying the same risks of abuse, misuse, addiction or adverse effects associated with some oral treatments. As many as 54% of treated patients in the 3-month group and 60% of treated patients in the 6-month group de-escalated the use of concurrent pain medications compared to 4% and 6% in the untreated groups.
The untreated groups saw an increase in medication usage in 52% of cases (compared to only 10% for the treated group.)
Treated patients reported a preference for topical treatments both for their convenience and ease of use and 99.5% of patients reported no side effects while using the topical treatments.
Callitas Health relaunches ToConceive personal lubricant
CINCINNATI — Callitas Health (formerly M Pharmaceutical) last week announced the market re-launch of ToConceive, a fertility enhancing vaginal gel, lubricant and moisturizer that may aid in creating an optimal environment for natural conception. The newly reformulated moisturizer is now paraben-free to prevent potential negative side effects on hormones and includes only pharmaceutical-grade ingredients to help increase natural lubrication.
The newly re-launched product is Health Canada compliant and has been available for purchase online as of Sept. 29, 2017.
Based on the science behind the 2010 Nobel Prize in Medicine for in vitro fertilization (IVF) and sperm capacitation, ToConceive was scientifically developed by Ronald Thompson to assist in creating the right environment for conception. ToConceive, in studies, has been shown to help enhance a woman's own natural lubrication, which contains the proteins and other co-factors needed to help conceive naturally.
Acknowledging that approximately 75% of unexplained infertility cases among healthy couples can be traced back to a lack of natural vaginal lubrication, ToConceive provides couples trying to conceive with a natural, non-invasive and cost-effective product. The easy-to-apply patented gel includes key ingredients such as menthol and l-arginine, a naturally occurring amino-acid that help supports the production of nitric oxide, and in turn, may help stimulate blood flow to the vagina and other tissues.
"Recognizing both the financial and emotional burden that many couples experience while trying to conceive, ToConceive provides a cost-effective and minimally invasive option, as well as a community of couples who are undergoing similar journeys," said Lindsey Thompson, director brand management, Callitas Therapeutics. "Callitas Therapeutics is committed to shaping the future of healthcare, and ToConceive is a prime example of an innovative product that is paving-the-way for those seeking fertility assistance."
A 90-day supply of ToConceive is $129.99 and will available for purchase online, the company stated.
Bartell honors suppliers at 28th annual Vendor Breakfast
SEATTLE — Bartell Drugs took over the Seattle Aquarium Thursday to honor its supplier partners at its 28th annual Vendor Breakfast. The breakfast featured owners, CEOS, presidents and products representatives from more than 80 companies, including more than 25 that are locally based.
“Bartell Drugs is extremely appreciative of the relationships it has with its many vendors,” Bartell Drugs SVP merchandising said. “Building exceptional relationships with our community, customer and vendor partners allow us to deliver quality products and prices at the same time leaving room for a little fun.”
At the event, the chain presented several of its vendors with awards for work that went above and beyond to help the company, Bartell Drugs said. The Bartell Family Values Award for exceptional service was given to Bryan Nelson of Jensen Distribution services, the Sales Representative of the Year Award went to Reckitt Benckiser’s Michele Renz and the Local Vendor of the year Award went to Lane McVicker and Jean Thompson of Seattle Chocolate.
“Our vendor partnerships are vital to the success of our business,” Beebe said. “Their cooperation helps drive forward our initiatives to create a shopping environment that highlights popular product lines, brings quality local products to the forefront, promotes convenience and, of course, creates exceptional customer service experiences.”
The company also recognized the conservation work of the Seattle Aquarium by donating $3,000 to its Octopus Protection Project and presenting associate curator Joel Hollander with a gift basket of local treats.